Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation

Documenti analoghi

• Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
  di: Kim, Eun Young, et al.
  Pubblicazione: (2018)
• Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation
  di: Kim, Eun Young, et al.
  Pubblicazione: (2019)
• EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
  di: Chen, Yang, et al.
  Pubblicazione: (2018)
• A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
  di: Zhang, Nana, et al.
  Pubblicazione: (2017)
• EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
  di: Chen, Zhi-Yong, et al.
  Pubblicazione: (2012)